Pharma Patent Cliffby readouts.io
Loss of exclusivity · US · 2025–2037

The patent cliff by therapeutic area

$433.1B in 2025 worldwide sales of blockbuster drugs lose US exclusivity between 2025 and 2037. Cardiometabolic is the largest share, with $129.8B. Select an area for its drugs, dates and the companies most exposed.

Sales losing US exclusivity, by area

Cardiometabolic $129.8B 13 drugs: Mounjaro, Ozempic, Eliquis, Zepbound and 9 more Oncology $126.0B 20 drugs: Keytruda, Darzalex, Opdivo, Tagrisso and 16 more Immunology $86.4B 13 drugs: Dupixent, Skyrizi, Rinvoq, Cosentyx and 9 more Other areas $33.0B 7 drugs: Trikafta, Vabysmo, Ultomiris, Prolia and 3 more Neuroscience $24.4B 5 drugs: Ocrevus, Kesimpta, Vyvgart, Invega Sustenna and 1 more Infectious disease $17.1B 2 drugs: Biktarvy and Descovy Vaccines $16.4B 3 drugs: Prevnar 20, Gardasil and Shingrix

Each segment is one drug's 2025 worldwide sales. Drugs are counted in the area of their main use.

Share, cite or embed

Post on X Share on LinkedIn Email

Cite

Pharma Patent Cliff by readouts.io. "The patent cliff by therapeutic area." Updated 8 October 2026. https://pharmapatentcliff.com/areas

Embed

Free to use on your site with the source link. It shows the latest data whenever the page loads.

Preview